European law firm Fieldfisher has advised Panmure Gordon (UK) Limited in connection with the admission to AIM of Cambridge-based medical technology pioneer Horizon Discovery Group plc. Panmure acted as nominated adviser and broker to Horizon.
Horizon was admitted to AIM today with a market capitalisation of £120.5 million. Panmure raised approximately £68.5 million from institutional investors on behalf of Horizon and selling shareholders. This is one of the largest fundraisings on AIM this year.
Horizon is a revenue-generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines. Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools. Horizon's aim is to become a global market-leader in the provision of life science research tools that assist with determining the genetic basis of disease, and developing medicines which are tailored to an individual's DNA. The company generated revenue of £6.6 million last year.
The Fieldfisher team was led by equity capital markets partner Dominic Gurney-Champion. He was assisted by life sciences expert Dr. Beatriz San Martin and equity capital markets associate Ed Westhead.
Dominic Gurney-Champion said: "We are delighted to have acted for Panmure in connection with Horizon's admission to AIM, in what was one of the biggest fundraisings on AIM this year. Our team's combined equity capital market and life sciences experience meant that we were well placed to advise in connection with this transaction."
Sign up to our email digest